Plain-English translation of NCT05737303 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether nab-paclitaxel, a newer form of chemotherapy, works better than the standard solvent-based paclitaxel for treating advanced ovarian cancer and related cancers. The medication has shown promise in treating other cancers and may cause fewer allergic reactions than the older version. The study will compare how well both treatments work and how many side effects patients experience.
The standard chemotherapy treatment can cause serious allergic reactions in many patients. This medication is designed to work just as well but may be safer and easier to tolerate, which could help more patients complete their full course of treatment.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive one of four chemotherapy schedules—either the newer medication or the standard treatment, given either every three weeks or weekly over 6 cycles (about 4–5 months total). You will visit the clinic regularly to receive your infusions, have blood tests, and be monitored for side effects. The trial will track how well your cancer responds and how you tolerate the treatment.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China